The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1384
February 20, 2012
View Complete Issue         Table of Contents 2019 
Deferiprone (Ferriprox) for Iron Overload
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Deferiprone (Ferriprox) for Iron Overload
February 20, 2012 (Issue: 1384)
The FDA has approved deferiprone (de fer’ i prone; Ferriprox – ApoPharma), an oral chelating agent available in Europe since 1999, for use as a second-line treatment of iron overload due to blood transfusions (transfusional hemosiderosis) in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deferiprone (Ferriprox) for Iron Overload
Article code: 1384c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.